Welcome to our dedicated page for Personalis SEC filings (Ticker: PSNL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Personalis's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Personalis's regulatory disclosures and financial reporting.
Personalis, Inc. executive Aaron Tachibana, the CFO and COO, reported an option exercise and related share sale. On May 29, 2026, he exercised stock options to acquire 38,799 shares of Common Stock at an exercise price of $9.16 per share, then sold the same 38,799 shares in open-market transactions at a weighted average price of $11.58 per share, with individual sale prices ranging from $11.50 to $11.71.
The filing notes these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025. Following the sale, Tachibana directly holds 198,833 shares of Common Stock and 68,832 stock options that remain outstanding and are fully vested and exercisable, with an expiration date of March 13, 2029.
Personalis, Inc. reported that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for its ultrasensitive NeXT Personal test. As of May 19, 2026, coverage now includes monitoring response to neoadjuvant therapy in patients with Stage II–III triple‑negative or HER2‑positive breast cancer.
Personalis, Inc. director Karin Eastham received new equity awards. She was granted 6,250 shares of common stock in the form of restricted stock units and 37,500 stock options with an exercise price of $6.04 per share.
Both the RSUs and options vest 100% on the earlier of the one-year anniversary of the May 12, 2026 grant date or the day before Personalis’ next annual stockholder meeting, subject to continuous service. They also fully vest immediately before a qualifying Change in Control. After these grants, she directly holds 22,366 common shares and 37,500 options.
Personalis, Inc. director Blaine A. Bowman received new equity awards as part of his compensation. He was granted 6,250 restricted stock units, each representing one share of common stock, and 37,500 stock options to buy common shares at an exercise price of $6.04 per share.
The RSUs and options each vest 100% on the earlier of the one-year anniversary of the grant date or the day before the next annual stockholder meeting, contingent on his continuous service under the company’s 2019 Equity Incentive Plan. Both awards fully accelerate and vest immediately before any qualifying Change in Control. Following the RSU grant, Bowman directly holds 19,756 shares of common stock.
Personalis, Inc. director Kenneth J. Widder reported equity awards consisting of restricted stock units and stock options. He was granted 6,250 shares of Common Stock, represented by RSUs that each convert into one share upon settlement, and now holds 6,250 common shares directly after this award.
He also received a stock option for 37,500 shares of Common Stock at an exercise price of $6.04 per share, expiring on May 12, 2036. For both the RSUs and the option, 100% of the shares vest on the earlier of one year from the grant date or the day prior to the next annual stockholders’ meeting, subject to his continuous service. In the event of a Change in Control as defined in the company’s 2019 Equity Incentive Plan, the awards vest in full immediately before that transaction becomes effective.
Personalis, Inc. director Lonnie Shoff reported equity compensation in the form of restricted stock units (RSUs) and stock options. Shoff received 6,250 shares of common stock represented by RSUs at no cash cost, increasing direct common stock holdings to 37,190 shares after the grant.
Shoff was also granted options to buy 37,500 shares of common stock at an exercise price of $6.04 per share, expiring on May 12, 2036. Both the RSUs and options vest 100% on the earlier of one year from the grant date or the day prior to the next annual stockholder meeting, with full vesting accelerated immediately before a qualifying Change in Control.
Personalis, Inc. director Olivia Kyusuk Bloom reported equity compensation awards consisting of restricted stock units (RSUs) and stock options. She received 6,250 RSUs, each representing one share of common stock upon settlement, and 37,500 stock options with an exercise price of $6.04 per share. The filing states that 100% of both the RSUs and options vest on the earlier of the one-year anniversary of the May 12, 2026 grant date or the day prior to the company’s next annual meeting of stockholders, subject to her continuous service under the 2019 Equity Incentive Plan. In the event of a Change in Control, the RSUs and options vest immediately before that transaction becomes effective. After the RSU grant, Bloom directly owns 27,265 shares of common stock.
Personalis, Inc. director Woodrow A. Myers Jr. received equity compensation in the form of restricted stock units and stock options. He was granted 6,250 RSUs, each representing one share of common stock, bringing his direct common stock holdings to 32,366 shares after the award.
He was also granted options covering 37,500 shares of common stock at an exercise price of $6.04 per share, expiring on May 12, 2036. Both the RSUs and options vest 100% on the earlier of one year from the grant date or the day before the next annual stockholder meeting, with accelerated vesting immediately before a qualifying Change in Control if he remains in Continuous Service.